Cargando…
Coronary revascularisation in patients with chronic kidney disease and end‐stage renal disease: A meta‐analysis
OBJECTIVES: To compare coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) for revascularising coronary arteries in patients with chronic kidney disease (CKD) and end‐stage renal disease (ESRD). CKD is described as a continuous decrease in the glomerular filtration ra...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596450/ https://www.ncbi.nlm.nih.gov/pubmed/34117687 http://dx.doi.org/10.1111/ijcp.14506 |
_version_ | 1784600382070063104 |
---|---|
author | Li, Xihui Xiao, Feng Zhang, Siyu |
author_facet | Li, Xihui Xiao, Feng Zhang, Siyu |
author_sort | Li, Xihui |
collection | PubMed |
description | OBJECTIVES: To compare coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) for revascularising coronary arteries in patients with chronic kidney disease (CKD) and end‐stage renal disease (ESRD). CKD is described as a continuous decrease in the glomerular filtration rate or abnormalities in kidney structure or function. METHODS: PubMed, Cochrane Library and Embase databases were searched for studies on the revascularisation of coronary arteries in patients with CKD and ESRD. RESULTS: Since no randomised controlled trials (RCTs) have addressed this issue so far, 31 observational studies involving 74 805 patients were included in this meta‐analysis. Compared with PCI, patients undergoing CABG have significantly higher early mortality (CKD: RR = 1.62, 95% CI: 1.17‐2.25, pheterogeneity = 0.476, I (2) = 0; ESRD: RR = 1.99, 95% CI: 1.46‐2.71, pheterogeneity = 0.001, I (2) = 66.9%). Patients with ESRD undergoing CABG have significantly lower all‐cause mortality (RR = 0.95, 95% CI: 0.93‐0.96, pheterogeneity < 0.001, I (2) = 82.9%) and cardiac mortality (RR = 0.73, 95% CI: 0.58‐0.92, pheterogeneity = 0.908, I (2) = 0). The long‐term risk of repeat revascularisation (CKD: RR = 0.24, 95% CI: 0.19‐0.30, pheterogeneity = 0.489, I (2) = 0; ESRD: RR = 0.23, 95% CI: 0.15‐0.34, pheterogeneity = 0.012, I (2) = 54.4%) and myocardial infarction (CKD: RR = .57, 95% CI: 0.38‐0.85, pheterogeneity = 0.025, I (2) = 49.9%; ESRD: RR = 0.42, 95% CI: 0.40‐0.44, pheterogeneity = 0.49, I (2) = 0) remained significantly higher in the PCI group. CONCLUSIONS: Patients with ESRD, but not CKD, who underwent CABG had significantly lower all‐cause mortality and cardiac mortality. However, CABG was associated with an increased risk of early mortality in patients with CKD or ESRD. Adequately powered, contemporary, prospective RCTs are needed to define the optimal revascularisation strategy for patients with CKD and ESRD. |
format | Online Article Text |
id | pubmed-8596450 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85964502021-11-22 Coronary revascularisation in patients with chronic kidney disease and end‐stage renal disease: A meta‐analysis Li, Xihui Xiao, Feng Zhang, Siyu Int J Clin Pract Meta‐analysis OBJECTIVES: To compare coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) for revascularising coronary arteries in patients with chronic kidney disease (CKD) and end‐stage renal disease (ESRD). CKD is described as a continuous decrease in the glomerular filtration rate or abnormalities in kidney structure or function. METHODS: PubMed, Cochrane Library and Embase databases were searched for studies on the revascularisation of coronary arteries in patients with CKD and ESRD. RESULTS: Since no randomised controlled trials (RCTs) have addressed this issue so far, 31 observational studies involving 74 805 patients were included in this meta‐analysis. Compared with PCI, patients undergoing CABG have significantly higher early mortality (CKD: RR = 1.62, 95% CI: 1.17‐2.25, pheterogeneity = 0.476, I (2) = 0; ESRD: RR = 1.99, 95% CI: 1.46‐2.71, pheterogeneity = 0.001, I (2) = 66.9%). Patients with ESRD undergoing CABG have significantly lower all‐cause mortality (RR = 0.95, 95% CI: 0.93‐0.96, pheterogeneity < 0.001, I (2) = 82.9%) and cardiac mortality (RR = 0.73, 95% CI: 0.58‐0.92, pheterogeneity = 0.908, I (2) = 0). The long‐term risk of repeat revascularisation (CKD: RR = 0.24, 95% CI: 0.19‐0.30, pheterogeneity = 0.489, I (2) = 0; ESRD: RR = 0.23, 95% CI: 0.15‐0.34, pheterogeneity = 0.012, I (2) = 54.4%) and myocardial infarction (CKD: RR = .57, 95% CI: 0.38‐0.85, pheterogeneity = 0.025, I (2) = 49.9%; ESRD: RR = 0.42, 95% CI: 0.40‐0.44, pheterogeneity = 0.49, I (2) = 0) remained significantly higher in the PCI group. CONCLUSIONS: Patients with ESRD, but not CKD, who underwent CABG had significantly lower all‐cause mortality and cardiac mortality. However, CABG was associated with an increased risk of early mortality in patients with CKD or ESRD. Adequately powered, contemporary, prospective RCTs are needed to define the optimal revascularisation strategy for patients with CKD and ESRD. John Wiley and Sons Inc. 2021-06-29 2021-11 /pmc/articles/PMC8596450/ /pubmed/34117687 http://dx.doi.org/10.1111/ijcp.14506 Text en © 2021 The Authors. International Journal of Clinical Practice published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Meta‐analysis Li, Xihui Xiao, Feng Zhang, Siyu Coronary revascularisation in patients with chronic kidney disease and end‐stage renal disease: A meta‐analysis |
title | Coronary revascularisation in patients with chronic kidney disease and end‐stage renal disease: A meta‐analysis |
title_full | Coronary revascularisation in patients with chronic kidney disease and end‐stage renal disease: A meta‐analysis |
title_fullStr | Coronary revascularisation in patients with chronic kidney disease and end‐stage renal disease: A meta‐analysis |
title_full_unstemmed | Coronary revascularisation in patients with chronic kidney disease and end‐stage renal disease: A meta‐analysis |
title_short | Coronary revascularisation in patients with chronic kidney disease and end‐stage renal disease: A meta‐analysis |
title_sort | coronary revascularisation in patients with chronic kidney disease and end‐stage renal disease: a meta‐analysis |
topic | Meta‐analysis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596450/ https://www.ncbi.nlm.nih.gov/pubmed/34117687 http://dx.doi.org/10.1111/ijcp.14506 |
work_keys_str_mv | AT lixihui coronaryrevascularisationinpatientswithchronickidneydiseaseandendstagerenaldiseaseametaanalysis AT xiaofeng coronaryrevascularisationinpatientswithchronickidneydiseaseandendstagerenaldiseaseametaanalysis AT zhangsiyu coronaryrevascularisationinpatientswithchronickidneydiseaseandendstagerenaldiseaseametaanalysis |